Company Overview and News

 
Caely shares fall on profit-taking

2018-04-27 thestar.com.my
KUALA LUMPUR: Caely Holdings Bhd ’s shares were traded lower in morning trade Friday as investors take profit after the recent gains.

 
Caely plans tie-up with China lingerie firms

2018-04-23 thestar.com.my
KUALA LUMPUR: Undergarments manufacturer Caely Holdings Bhd is in talks with several China-based lingerie companies to expand its earnings and business prospects. The company announced on Monday this was part of its strategy to expand its market share by working with lingerie companies in the region. Caely sells its products in Malaysia and it also exports to Europe, Canada, the US and other countries.

 
Trading ideas: Ni Hsin, Caely, Comfort Gloves, Suria Capital, MMC

2018-04-09 thestar.com.my
KUALA LUMPUR: Ni Hsin Resources Bhd , Caely Holdings Bhd , Comfort Gloves Bhd , Suria Capital Holdings Bhd and MMC Corp Bhd are among the stocks to watch on Monday, according to JF Apex Research.

 
Caely shares fell 5% despite bonus issues proposal

2018-01-17 thestar.com.my
KUALA LUMPUR: Caely Holdings Bhd ’s shares fell 4% in early trade after announcing that it has proposed to undertake a bonus issue of warrants on the basis of one warrant for every two existing shares held.

 
Trading ideas: TM, TNB, MBSB, Caely, UMW O&G

2018-01-17 thestar.com.my
KUALA LUMPUR: Telekom Malaysia Bhd , Tenaga Nasional Bhd , Malaysia Building Society Bhd (MBSB) and Caely Holdings Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.

 
Caely plans free warrants issue

2018-01-16 thestar.com.my
KUALA LUMPUR: Caely Holdings Bhd is proposing to issue free warrants to entitled shareholders, as the maker of ladies undergarments seeks to raise funds without diluting its shareholders’ stake in the company.

 
Caely shares down after Bursa UMA query

2018-01-05 thestar.com.my
KUALA LUMPUR: Shares of Caely Holdings Bhd fell after Bursa Malaysia Securities Bhd issued an uma query on its stock, which hit limit-up on Thursday.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

7h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...